ALKERMES | ALKS - Sales Revenues


ALKERMES reported $496.01M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
ALKERMES USD 496.01M 103.1M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 22.97B 3.17B Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 268M 22M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Merck USD 16.6B 310M Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Otsuka Holdings JPY 702.05B 71.71B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026